EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? – a critical appraisal

Qinghua Ke, Shiqiong Zhou

Frontiers in Oncology · 15.04.2026 · 16

DOI: 10.3389/fonc.2026.1822293 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 15.04.2026. Verfasst von Qinghua Ke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemoradiotherapy, The First People's Hospital of Jingzhou, Jingzhou, Hubei, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of relapsed/refractory multiple myeloma with true extramedullary disease (EMD) remains a critical challenge. The phase 2 RedirecTT-1 study evaluated the combination of two bispecific antibodies, talquetamab (anti-GPRC5D) and teclistamab (anti-BCMA), in this high-risk population. While the reported overall response rate of 79% and 12-month progression−free survival of 61% are promising, a balanced interpretation requires caution. The single−arm design, short follow−up (12.6 months), and indirect comparisons with CAR−T therapy preclude definitive conclusions about comparative effectiveness. Notably, grade 3–4 infections occurred in 31% of patients, with five treatment−related deaths – a toxicity burden that may limit real−world implementation outside specialized centers. Responses were observed after prior BCMA−directed CAR−T therapy, but heterogeneity within this subgroup (time from CAR−T to progression ranging from 98 to 1030 days) tempers enthusiasm for universal sequencing strategies. Key unresolved questions include optimal sequencing with CAR−T, mechanisms of resistance, predictive biomarkers, and the feasibility of delivering this intensive regimen in routine practice. This commentary argues that dual bispecific therapy is a potent but still investigational option for EMD, and its definitive positioning requires randomized data and head−to−head comparisons.

Schlagwörter

Stichwörter der Autor:innen

CAR - T therapybispecific antibodiescritical appraisalextramedullary myelomaimmunotherapy sequencingtalquetamabteclistamab

Autor:innen und Institutionen

  • Department of Chemoradiotherapy, The First People's Hospital of Jingzhou, Jingzhou, Hubei, China.

Zitieren

APA

Ke, Q., & Zhou, S. (2026). Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? – a critical appraisal. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1822293

Vancouver

Ke Q, Zhou S. Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? – a critical appraisal. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1822293

BibTeX
@article{Ke2026,
  author = {Ke, Qinghua and Zhou, Shiqiong},
  title = {Beyond dual targeting: redefining the treatment horizon for true extramedullary myeloma? – a critical appraisal},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1822293}
}
Kostenlos starten →